Pharmaceutical industry
Cambridge-based BBN Software Products Corporation, a leading provider of clinical trials data management software, has announced a significant contract with Ciba's Pharma Division, a global pharmaceutical company, to standardize on BBN's ClintrialTM software for its worldwide drug development projects. The contract marks the largest Clintrial purchase
Pharmaceutical industry
A recent national television appearance by Dr. James Braly, Medical Director of Immuno Laboratories, has exposed alarming statistics regarding Otitis Media, a prevalent middle ear infection affecting children. According to Dr. Braly, shocking figures include a 224% increase in Otitis Media cases among children under 2 years old, with over
Pharmaceutical industry
As more than 1,300 biotechnology companies worldwide pursue their fortunes in the biopharmaceutical market, the majority are facing difficulties in building their own manufacturing facilities due to dwindling investment funds. Approximately 1,300 biotechnology companies are seeking to establish a presence in the biopharmaceutical market, but investment funds are
Pharmaceutical industry
OXIS International Inc., a leader in antioxidant therapeutic technologies, announced its intention to acquire Philadelphia-based Therox Pharmaceuticals Inc., which is funded by S.R. One, Limited, and Brantley Venture Partners II L.P. This acquisition comes as the third in less than a year for OXIS, and is expected to
Pharmaceutical industry
Baywood International, Inc., a leading developer of proprietary health and wellness products, has announced a major distribution agreement with Omegamed Pharmaceuticals Limited, a prominent distributor of pharmaceutical products in Brazil. As part of this agreement, Omegamed has acquired the rights to distribute Baywood's dietary and weight reduction products,
Pharmaceutical industry
PSE&G, a leading energy company, and Merck, a global healthcare and pharmaceutical company, announced a groundbreaking partnership to address the ozone non-attainment problem in the Northeast. The two companies entered into a trade of emission reduction credits, allowing Merck to purchase surplus discrete emission reductions (SDRs) from PSE&
Pharmaceutical industry
Bipolar disorder, affecting over 2 million Americans, has received a major breakthrough in treatment with the indication of Depakote (divalproex sodium) tablets for manic episodes. This is the first medication approved in 25 years for this specific use. Depakote has shown significant improvement in manic symptoms in patients compared to
Pharmaceutical industry
Novavax Inc.'s experimental vaccine against Shigella flexneri 2a, a bacterium that causes gastrointestinal infections worldwide, has been cleared for human testing by the US Food and Drug Administration (FDA). The novel vaccine, known as Novasome, is a lipid vesicle-based oral vaccine that has shown promising results in animal
Pharmaceutical industry
Biogen, Inc. has made significant progress in its efforts to bring its recombinant interferon beta product, AVONEX, to market. The company has filed for U.S. Food and Drug Administration (FDA) approval, marking a crucial milestone in the development of this treatment for multiple sclerosis (MS). According to Jim Vincent,
Drugs
Bristol-Myers Squibb Company has exercised its exclusive option to license Phyton's proprietary plant cell culture technology for the production of the anticancer drug TAXOL(R) (paclitaxel) and various related substances. This technology represents a new method of producing paclitaxel that requires neither the bark of trees nor cultivated
Drugs
Repligen Corporation, a global biopharmaceutical company, has launched Allegro Biologics, a strategic business unit focused on process development and manufacturing. The new division, led by Ashley Lawton, Ph.D., marks a significant expansion of Repligen's capabilities in the biotechnology and pharmaceutical industries. Allegro Biologics is poised to capitalize
Drugs
Value Health, Inc., a leading provider of specialty managed care benefit programs and health care information services, has announced that the Federal Trade Commission (FTC) has granted early termination of the Hart-Scott-Rodino waiting period for its acquisition of Diagnostek, Inc. This development enables Value Health to move forward with the
